We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Filaxis (commercial partner, Latin America — Ampligen in Argentina); AstraZeneca Imfinzi (durvalumab) used in combination in investigator-initiated DURIPANC study at Erasmus MC (no agreement terms disclosed)
Indications
Metastatic pancreatic cancer (with Imfinzi/durvalumab, post-FOLFIRINOX)(Phase 2)
Locally advanced pancreatic cancer (AMP-270)(Phase 2)
ME/CFS and post-COVID fatigue(Phase 2)
Advanced recurrent ovarian cancer(Phase 2)
Influenza vaccine adjuvant (with FluMist; includes avian influenza)(Stage not disclosed)
Catalysts
— later in 2026
Status note Company's stated focus is Ampligen in late-stage pancreatic cancer following its pancreatic-cancer Early Access Program; anticipated Phase 3 design work under Mar 2026 agreement with PPD clinical research (Thermo Fisher), trial not yet initiated. AMP-518 (post-COVID conditions) completed 2023; close-out finished 2025; final results posted to ClinicalTrials.gov Jan 2025. Phase 1 portion of DURIPANC led to ongoing Phase 2 portion; all subjects enrolled and dosed as of Jun 30, 2026.
Alferon N Injection
Approved · Active
Aliases Interferon alfa
Target Interferon alfa receptor (IFNAR)
Indications
Condylomata acuminata (genital warts)(Approved)
Status note Approved commercial product; commercial sales halted due to lack of finished goods inventory per this filing.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 4 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.